PDK4 and neoplasm: PDK4 upregulation in stromal cells causes elevated cancer aggressiveness, particularly drug resistance, while targeting PDK4 restrains cancer malignancy in vitro, promotes tumor regression in vivo and extends animal post-treatment survival.